BPC-157 + Thymosin Alpha-1 Stack: When to Pick One Over the Stack

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

What are the two peptides?

BPC-157 is a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice [1]. It is not an FDA-approved drug. No FDA-approved product contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract [2]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US and is not interchangeable with bulk peptide powder [2]. It has four US orphan drug designations, which is a separate process from approval and is not an approval [2]. It is approved as a medicine in some other countries: Italy, as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [2].

Do they work through different pathways?

Thymosin alpha-1 has a described immune mechanism. It is described as an immune modulator that augments T-cell function [8], and it is thought to signal through Toll-like receptors on myeloid and plasmacytoid dendritic cells, triggering cytokine production [9]. After subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours, is cleared with a half-life of about 1.8 to 2.6 hours, and does not accumulate over five daily doses [2].

For BPC-157, the mechanism is not established in people. FDA's July 2026 review says its molecular targets have not been identified, its mechanisms remain poorly understood, and dose-response relationships for the reported protective effects were not established; those reported effects come from rat studies, not human trials [1].

What human evidence exists for BPC-157?

A systematic review searched through June 1, 2026 and found only three human studies of BPC-157 in orthopaedic and regenerative use, covering 30 patients in total, all of poor methodological quality with certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [4].

Those three studies were:

• A retrospective chart review at one Florida clinic: 17 patients, 16 reached by phone, including 12 given BPC-157 alone. Of those 12, 11 (91.6%) reported significant improvement. There was no control group, no validated outcome tool, and results were recalled by patients [10].
• A pilot in 12 women aged 39 to 76 with interstitial cystitis who had not responded to pentosan polysulfate. They received a total of 10 mg injected around the inflamed bladder wall in one procedure; 10 of 12 reported complete symptom resolution and 2 reported about 80%. It was a single arm, patient-rated study [11].
• An intravenous safety pilot in 2 adults given 10 mg on day 1 and 20 mg on day 2, with no measurable change in the heart, liver, kidney, thyroid or glucose markers tested and no side effects reported. Two people cannot establish safety [12].

FDA's own review found five small human studies. One was a randomized trial of 53 people with mild to moderate ulcerative colitis given an 80 mg BPC-157 enema or placebo daily for 2 weeks; the results were reported only in summary form at a conference, and FDA said there was too little detail to judge effectiveness [1]. FDA found no human studies of BPC-157 given by mouth, subcutaneous injection, nasal spray or on the skin [1].

What human evidence exists for thymosin alpha-1?

The largest synthesis is a 2026 Cochrane review: 10 randomized trials, 1,349 adults with chronic hepatitis B, published between 1991 and 2018 in Bangladesh, China, Italy, Korea, Singapore and Taiwan [3]. There was a possible reduction in all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) but the certainty was very low, with little to no effect on quality of life or liver histology, and the reviewers said they are not sure it helps [3]. It may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [3].

Individual trials are mixed. In a double-blind placebo-controlled trial of 98 adults with HBeAg-positive hepatitis B, adding thymosin alpha-1 to interferon produced HBeAg loss at 72 weeks in 45.8% versus 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), which was not statistically significant [13]. A 1991 pilot in just 12 people reported hepatitis B virus DNA clearance in 6 of 7 treated patients versus 1 of 5 on placebo (P<0.04) [14]. For hepatitis C, a 2010 review concluded that trials had not conclusively supported a role for thymosin alpha-1 in interferon-based therapy [15].

So when does picking one over the stack make sense?

The evidence supports matching the peptide to the question being asked, not to a theory of complementary pathways.

Knee pain or bladder symptoms. BPC-157 has only limited human evidence from small, uncontrolled studies, and its benefit remains uncertain [4]. Thymosin alpha-1's human evidence is in chronic hepatitis B, not in these conditions [3].

Chronic hepatitis B. Thymosin alpha-1 is the one with randomized trials here, and even that benefit is rated very uncertain [3]. The BPC-157 human studies described above did not address hepatitis B [1][4].

Uses that regulators outside the US have authorized. Thymosin alpha-1 has regulator-authorized uses outside the United States, including as an influenza-vaccine adjuvant in Italy and for chronic hepatitis B in India; it is not FDA-approved [2]. In Italy, Zadaxin is given subcutaneously or intramuscularly at 1.6 mg twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second [2]. BPC-157 has nothing comparable.

Competition sport. A stack is ruled out for any tested athlete, because BPC-157 is the prohibited half. WADA names BPC-157 in S0 (non-approved substances) and it is prohibited at all times, in and out of competition; the 2026 List has been in force since January 1, 2026 [7]. Thymosin alpha-1 is not named on the 2026 or 2027 List [7][16].

What do the safety data show?

Only Zadaxin has a label among these two products, and it is not a US label. The Italian prescribing information says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [2].

BPC-157 has no label. FDA concluded there is insufficient clinical safety information to characterize its safety profile [1]. In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small, and gave limited safety information [1]. In 28-day intramuscular animal studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

FDA's search of its adverse-event database through December 4, 2025 turned up only three reports, all involving injectable BPC-157: injection-site redness and swelling lasting 9 days in a patient who was also using a compounded thymosin product; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused any of them [1].

For thymosin alpha-1, FDA's adverse-event database search on April 22, 2024 found zero reports [2]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses given after marketing, with adverse experiences described as infrequent and mild; this is company-linked data [2].

Are either approved, and can they be compounded?

Neither is FDA-approved. BPC-157 currently sits in the nominated-but-withdrawn table on FDA's page about bulk substances that may present significant safety risks, after having been in the significant-safety-risk category from September 2023 until April 22, 2026, when the nominators withdrew. FDA's stated concerns about immunogenicity, peptide impurities and insufficient safety information are still posted, and removal was not a finding of safety [17]. BPC-157 is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, so FDA's category-1 no-action policy does not cover it [18].

FDA staff recommended against adding BPC-157 to the pharmacy bulks list in July 2026, citing poor chemical characterization, little safety and immunogenicity information, and insufficient evidence for the ulcerative colitis use FDA evaluated. The Pharmacy Compounding Advisory Committee voted in favor of adding it anyway, reported as 8 to 6 with 1 abstention; that vote is advice only, and listing requires formal rulemaking [1][19]. In October 2026 HHS issued a draft enforcement-discretion policy naming BPC-157 among six peptides [6]. It is a draft, it does not put BPC-157 on any list, it does not establish rights and is not binding, and HHS may revisit it [6][5]. Its conditions include BPC-157 acetate only, a single active ingredient, and subcutaneous, intramuscular, oral or topical forms (nasal, rectal and intravenous are not listed) [5]. A product combining BPC-157 with thymosin alpha-1 would not meet the single-active-ingredient condition [5].

Thymosin alpha-1 is not one of the six peptides in that draft policy [5], and it is in none of the three categories on FDA's list for state-licensed pharmacies and physicians [18]. It appears in category 3 (nominated without adequate support) on FDA's list for outsourcing facilities, updated March 2025 [20]. In December 2024 the advisory committee voted 4 yes and 17 no on both the free base and the acetate, with members who voted no citing no compelling evidence of clinical effectiveness and safety [21]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [6].

Is thymosin alpha-1 the same as TB-500?

No. WADA names thymosin-beta-4 and its derivatives such as TB-500 in S2.3 (growth factors), which is a different peptide from thymosin alpha-1, and thymosin alpha-1 is not named on the Prohibited List [7].